Andrew Farah and Gauri Madan
Pediatric depression remains a treatment challenge, not only because of its increasing prevalence over the past year, but the “black box warning,” which elaborates the possibility of suicidal thoughts or behaviors associated with antidepressant use in younger patients. We report a case series of pediatric patients, the majority of whom achieved remission of their depressive illnesses utilizing B vitamin-based coenzymes as monotherapy, and some of whom required an antidepressant medication added to daily coenzymes as adjunctive therapy. No patient reported side effects, and none reported an increase in suicidal thoughts utilizing B-vitamin-based, coenzyme therapy. The authors believe further study is needed to explore this safe treatment option for some of our most vulnerable patients.
